Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Descartes-11 consolidation in high-risk multiple myeloma
NCT04436029Phase 2Completed
- Sponsor
- Cartesian Therapeutics
- Start
- Feb 2021
- Primary completion
- Feb 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of Descartes-11 in multiple myeloma (MM), sponsored by Cartesian Therapeutics. Started Feb 2021; status: completed.
02
Drugs
Descartes-11
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04436029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04436029.